342 related articles for article (PubMed ID: 14649884)
21. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma.
Parney IF; Kunwar S; McDermott M; Berger M; Prados M; Cha S; Croteau D; Puri RK; Chang SM
J Neurosurg; 2005 Feb; 102(2):267-75. PubMed ID: 15739554
[TBL] [Abstract][Full Text] [Related]
22. Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.
Vogelbaum MA; Sampson JH; Kunwar S; Chang SM; Shaffrey M; Asher AL; Lang FF; Croteau D; Parker K; Grahn AY; Sherman JW; Husain SR; Puri RK
Neurosurgery; 2007 Nov; 61(5):1031-7; discussion 1037-8. PubMed ID: 18091279
[TBL] [Abstract][Full Text] [Related]
23. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.
Kunwar S; Prados MD; Chang SM; Berger MS; Lang FF; Piepmeier JM; Sampson JH; Ram Z; Gutin PH; Gibbons RD; Aldape KD; Croteau DJ; Sherman JW; Puri RK;
J Clin Oncol; 2007 Mar; 25(7):837-44. PubMed ID: 17327604
[TBL] [Abstract][Full Text] [Related]
24. IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer.
Kawakami K; Kawakami M; Puri RK
J Immunol; 2002 Dec; 169(12):7119-26. PubMed ID: 12471149
[TBL] [Abstract][Full Text] [Related]
25. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.
Rand RW; Kreitman RJ; Patronas N; Varricchio F; Pastan I; Puri RK
Clin Cancer Res; 2000 Jun; 6(6):2157-65. PubMed ID: 10873064
[TBL] [Abstract][Full Text] [Related]
26. Preclinical studies with IL-13PE38QQR for therapy of malignant glioma.
Joshi BH; Husain SR; Puri RK
Drug News Perspect; 2000 Dec; 13(10):599-605. PubMed ID: 12879131
[TBL] [Abstract][Full Text] [Related]
27. Combination fusion protein therapy of refractory brain tumors: demonstration of efficacy in cell culture.
Liu TF; Cohen KA; Willingham MC; Tatter SB; Puri RK; Frankel AE
J Neurooncol; 2003 Oct; 65(1):77-85. PubMed ID: 14649887
[TBL] [Abstract][Full Text] [Related]
28. Tumor regression mechanisms by IL-13 receptor-targeted cancer therapy involve apoptotic pathways.
Kawakami M; Kawakami K; Puri RK
Int J Cancer; 2003 Jan; 103(1):45-52. PubMed ID: 12455052
[TBL] [Abstract][Full Text] [Related]
29. Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors.
Kawakami M; Kawakami K; Takahashi S; Abe M; Puri RK
Cancer; 2004 Sep; 101(5):1036-42. PubMed ID: 15329913
[TBL] [Abstract][Full Text] [Related]
30. Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice.
Li C; Hall WA; Jin N; Todhunter DA; Panoskaltsis-Mortari A; Vallera DA
Protein Eng; 2002 May; 15(5):419-27. PubMed ID: 12034862
[TBL] [Abstract][Full Text] [Related]
31. Combined effects of radiation and interleukin-13 receptor-targeted cytotoxin on glioblastoma cell lines.
Kawakami K; Kawakami M; Liu Q; Puri RK
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):230-7. PubMed ID: 16111594
[TBL] [Abstract][Full Text] [Related]
32. Identification and characterization of interleukin-13 receptor in human medulloblastoma and targeting these receptors with interleukin-13-pseudomonas exotoxin fusion protein.
Joshi BH; Leland P; Puri RK
Croat Med J; 2003 Aug; 44(4):455-62. PubMed ID: 12950150
[TBL] [Abstract][Full Text] [Related]
33. Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts.
Kawakami K; Husain SR; Bright RK; Puri RK
Cancer Gene Ther; 2001 Nov; 8(11):861-8. PubMed ID: 11773976
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
Hall WA; Vallera DA
Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
[TBL] [Abstract][Full Text] [Related]
35. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin.
Joshi BH; Kawakami K; Leland P; Puri RK
Clin Cancer Res; 2002 Jun; 8(6):1948-56. PubMed ID: 12060640
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
Kioi M; Kawakami M; Shimamura T; Husain SR; Puri RK
Cancer; 2006 Sep; 107(6):1407-18. PubMed ID: 16902988
[TBL] [Abstract][Full Text] [Related]
37. Pancreatic cancer cells express interleukin-13 and -4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and -4.
Kornmann M; Kleeff J; Debinski W; Korc M
Anticancer Res; 1999; 19(1A):125-31. PubMed ID: 10226533
[TBL] [Abstract][Full Text] [Related]
38. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin.
Debinski W; Obiri NI; Powers SK; Pastan I; Puri RK
Clin Cancer Res; 1995 Nov; 1(11):1253-8. PubMed ID: 9815919
[TBL] [Abstract][Full Text] [Related]
39. Sensitization of cancer cells to interleukin 13-pseudomonas exotoxin-induced cell death by gene transfer of interleukin 13 receptor alpha chain.
Kawakami K; Joshi BH; Puri RK
Hum Gene Ther; 2000 Sep; 11(13):1829-35. PubMed ID: 10986556
[TBL] [Abstract][Full Text] [Related]
40. Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells.
Debinski W; Miner R; Leland P; Obiri NI; Puri RK
J Biol Chem; 1996 Sep; 271(37):22428-33. PubMed ID: 8798406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
